Therapies combining antibiotics and proton-pump inhibitors (PPIs) have been shown to be eective in clinical trials to eradicate Helicobacter pylori in peptic ulcer patients. Triple and quadruple therapies provide the highest eradication rates of more than 90%, while, for dual therapies, overall eradication rates with a maximum of 60±80% are commonly accepted [1±5]. Because this evidence is mainly based on results of clinical trials in peptic ulcer patients, we assessed the incidence of continued use of a PPI after H. pylori eradication and evaluated determinants associated with continued use after H. pylori eradication therapies in daily clinical practice. In such a setting, there will be, among others, a variety of prescribed treatment therapies in¯uencing outcomes considerably [6] .
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As part of a prospective observational follow-up study of 5669 lansoprazole users, 258 patients treated with lansoprazole as part of H. pylori eradication therapy in daily clinical practice were followed and evaluated [7] . Physicians collected data including, age, gender, primary indication of lansoprazole prescription, past use of acid-related drugs, eradication regimen and eradication success or failure. No speci®c tests were requested from the physician with regard to the primary diagnosis and the method used to assess eradication. A case-control design was used to compare patients with continued use of lansoprazole versus patients with no continued use of lansoprazole after H. pylori eradication therapy. Continued use was de®ned as a new lansoprazole prescription more than 14 days after start of the H. pylori eradication therapy. Baseline comparisons were calculated yielding odds ratios with a con®dence interval of 95%. Odds ratios were adjusted for all other given determinants using conditional logistic regression.
Triple therapy was most commonly prescribed (57.4%), followed by quadruple (21.7%) and dual (20.9%) therapies. These results were in accordance with literature stating triple therapy as standard therapy [2] . In total, 20 dierent combinations of drugs were used, increasing to over 50 individual therapy regimes when dosages were taken into account. In the majority of patients, the duration of eradication therapy was 5±7 days or, less frequently, 8±14 days.
We found that 41.1% of patients (106 of 258) continued PPI treatment after H. pylori eradication therapy (Fig. 1) . Patients with only gastro-oesophageal re¯ux disease (GORD) and patients treated with dual eradication therapies continued their PPI therapy most frequently in, respectively, 55.0% and 53.7%. Patients with a peptic ulcer without GORD and treated with quadruple and triple eradication therapies (n 90) showed continued use in 30.0%. A proportion of these patients with duodenal ulcer and treated for H. pylori may have developed GORD after cure and, therefore, a PPI was prescribed [8] . A small number of patients with gastric ulcer and treated for H. pylori may not yet have achieved cure, as, in these patients, a short-term treatment up to 8 weeks was recommended [9] . In general, PPIs may be prescribed as preventive therapy in peptic ulcer patients requiring chronic non-steroidal anti-in¯ammatory drug (NSAID) treatment [10] . However, we found only 5.1% of patients (2 of 39) using long-term NSAIDs among the patients with peptic ulcers and continued use.
As shown in Table 1 , GORD without peptic ulcer as diagnosis was signi®cantly associated with continued use with an adjusted odds ratio (95% CI) of 2.8 (1.1± 7.2). In patients with only GORD, continued PPI use is expected after H. pylori eradication therapy as maintenance therapy to prevent recurrences [11] . Of patients with`other' diagnoses, 44.7% (51 of 114) continued PPI treatment. A lack of symptom relief has been reported in patients with non-ulcer dyspepsia [12] . However, contrasting results exist, as also a symptomatic bene®t from eradicating H. pylori in patients with non-ulcer dyspepsia has been described [13] . Dual therapy was more frequently but not signi®cantly reported in patients with continued PPI use (27.4%) versus patients with no further PPI use (16.5%). Patients treated with dual H. pylori eradication therapies may continue their PPI therapy due to lower eradication rates of dual therapies than triple and quadruple ; an association with the primary diagnosis ulcer could not be established. Evaluation by a general practitioner or specialist, as well as gender and age, did not signi®-cantly dier between patients continuing PPI use and patients with no further PPI use. Eradication was achieved in 80.3% of the continued users (53 of 66) versus 91.1% of the patients with no further lansoprazole use (82 of 90); this dierence was not signi®cant. In the remaining patients, eradication success or failure was not assessed.
So, in a daily clinical practice setting, many patients with H. pylori eradication continued lansoprazole treatment (41.1%). This may partly be expected by GORD in the diagnosis or use of sub-eective eradication therapies, but even one of three peptic ulcer patients without GORD and treated with triple or quadruple therapies had continued PPI use. There are no indications that other PPIs demonstrate dierent user pro®les [14] . Additional research is necessary to investigate the impact of compliance and possibly other determinants on continued PPI use [15] . 
